Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Lymphoma, B-Cell 2Leukemia 2Burkitt Lymphoma 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Solid Tumors 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 4sacituzumab govitecan 3cabozantinib 3atezolizumab 3Taxes 3Paclitaxel 3Nivolumab 3Gemcitabine 3Biopsy 3eribulin 2erdafitinib 2Radiosurgery 2Platinum 2Ipilimumab 2Docetaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1tazemetostat 1sapanisertib 1olaparib 1enfortumab vedotin 1carotuximab 1Tomography, X-Ray Computed 1Suramin 1Panvac-VF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Transitional Cell × Echocardiography × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡